NASDAQ:CMPS
Compass Pathways PLC Stock News
$7.84
-0.150 (-1.88%)
At Close: May 17, 2024
Psychedelic companies say Compass study result validates industry's hope to find alternative treatments for mental health
07:30am, Thursday, 18'th Nov 2021
Hours after psychedelic leader Compass Pathways (NASDAQ:CMPS) announced Phase IIb results from the largest modern study on a psychedelic substance, the stocks of most psychedelic companies holistical
COMPASS Pathways (NASDAQ:CMPS) Upgraded by Zacks Investment Research to Hold
08:44am, Tuesday, 16'th Nov 2021 Dakota Financial News
Zacks Investment Research upgraded shares of COMPASS Pathways (NASDAQ:CMPS) from a sell rating to a hold rating in a research note published on Friday morning, Zacks.com reports. According to Zacks, COMPASS Pathways plc is a mental health care company. It operates principally in New York, USA. COMPASS Pathways plc is headquartered in London, UK. []
Is Now the Right Time to Buy Compass Pathways?
06:11am, Saturday, 13'th Nov 2021
Positive clinical trial results for psilocybin as a depression treatment didn't have the effect on the stock price that shareholders wanted.
Why Compass Pathways Stock Slumped This Week
08:17am, Friday, 12'th Nov 2021
Positive trial results weren't enough to keep the company's shares from sinking this week.
Behind the Wall: Psychedelics Have “Absolutely Transformational” Potential
10:42am, Thursday, 11'th Nov 2021
Is now the time to invest in psychedelic stocks? Dustin Robinson, founder of venture capital firm Iter Investments, says yes and explains why.
Is Compass Pathways Stock a Once-in-a-Lifetime Bargain?
10:00am, Thursday, 11'th Nov 2021
Investors might want to give this psychedelic stock another look.
Why Compass Pathways Shares Are Slumping More Than 22% Tuesday
03:48pm, Tuesday, 09'th Nov 2021
The stock dropped more than $13 on Tuesday.
Compass Pathways' Psilocybin Therapy Shows Mixed Results From Depression Trial
08:52am, Tuesday, 09'th Nov 2021
Compass Pathways plc (NASDAQ: CMPS) has announced results from Phase 2b trial of COMP360 psilocybin therapy for treatment-resistant depression. The study has achieved its primary end
Down 25% in 2021, Is Compass Pathways Undervalued?
06:55am, Friday, 22'nd Oct 2021
It depends on how optimistic you are about its lead program.
COMPASS Pathways is granted new US patent for crystalline psilocybin
07:00am, Tuesday, 19'th Oct 2021
London, UK – 19 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,
Why Compass Pathways Stock Dropped 12% in September
06:29pm, Tuesday, 05'th Oct 2021
Progress continues on the company's work to develop a mental health treatment using a psychoactive drug therapy.
COMPASS Pathways to participate in upcoming Maxim and Cantor investor conferences
08:00am, Tuesday, 21'st Sep 2021
London, UK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,
Is the Options Market Predicting a Spike in COMPASS Pathways (CMPS) Stock?
10:43am, Monday, 20'th Sep 2021
Investors need to pay close attention to COMPASS Pathways (CMPS) stock based on the movements in the options market lately.
Compass: Psychedelics Unicorn Expands Portfolio Beyond Psilocybin Into Psychedelics 2.0
03:39pm, Wednesday, 15'th Sep 2021
Psychedelics biotech company Compass Pathways (NASDAQ:CMPS) has purchased an intellectual property portfolio that includes patent applications for a variety of psychedelic and empathogenic substances.
COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs
07:00am, Tuesday, 14'th Sep 2021
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has acquired
